" class="no-js "lang="en-US"> Cerebral Therapeutics Names Julie Foster as COO
Saturday, May 18, 2024

Cerebral Therapeutics Names Julie Foster as Chief Operating Officer

Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today the appointment of MedTech industry veteran Julie Foster as Chief Operating Officer (COO). Julie succeeds John Foster who served as Cerebral Therapeutic’s President and COO since 2019, who will move into a business advisor role for the company.

Julie Foster is a seasoned leader with over 30 years of experience at Medtronic. She held positions of increasing responsibility across functional, regional, and general management roles. Most recently as VP of Customer Experience at Diabetes, VP of the Cardiac and Vascular businesses in EMEA, and General Manager of Pain Therapies and Targeted Drug Delivery business in Neuromodulation. She has a reputation as a strategic thought leader with strong business acumen who drives a customer focused, performance-driven culture, and leads business model innovation and change. Julie’s broad base of experience includes general management, global marketing, commercial operations, channel optimization, navigating complex regulatory and reimbursement requirements, and building diverse, high-performing teams.

As the new COO, Julie Foster will lead and scale the company’s growth and business operations, reporting to Dan Abrams, M.D., Chief Executive Officer of Cerebral Therapeutics. “Julie is a versatile leader who has demonstrated leadership in successfully developing and commercializing therapies for patients with serious unmet medical needs,” said Abrams. “Her impressive track record of empowering diverse teams to perform at their best to develop and launch new products and therapies will be key as we advance our portfolio starting with CT-010, our program for patients with severe medically refractory epilepsy. In addition, I would like to thank John Foster for his important contributions to the business over the last three plus years which enabled us to achieve our critical milestones, to advance our mission, and to grow as an organization.”

“It is a privilege to join this team of industry experts to advance Cerebral Therapeutics’ mission to improve the lives of patients suffering from severe neurological diseases for whom oral medicines are not effective or are limited by systemic side effects,” added Julie. “The unique approach and focus on the intracerebroventricular (ICV) route of administration has the potential to make a meaningful impact in the lives of many patients. The company’s strategy to develop, in-license, and co-develop new drug therapies using its proprietary ICV technology is groundbreaking and I’m pleased to help advance this meaningful work.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more